TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02116517

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green tea extract
Description: 500 mg three times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: 500 mg three times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cellulose 500mg three times a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: cellulose 500mg three times a day for 6 weeks
Study: NCT04403217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized structured dietary plan based on MD
Description: Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
Study: NCT00002529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
Study: NCT04587908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]
Description: ・Treatment period：oral administration for 52 weeks, BID after meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo [Ambulatory Cohort] only
Description: * Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal
Study: NCT02133001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
Study: NCT03778723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Description: Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Anesthesia
Description: Sevoflurane at a concentration of 2-2.5%
Study: NCT00002529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Description: Toremifene 60 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Description: Toremifene 60 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Description: Toremifene 60 mg daily.
Study: NCT01385579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care manager outreach
Description: Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
Study: NCT01681147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 online nutrition and exercise education classes
Description: Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 online nutrition and exercise education classes
Description: Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
Study: NCT03427255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT group treatment-plus
Description: The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT group treatment-plus
Description: The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list control condition
Description: Waiting-list control condition during length of active treatment (6 months).
Study: NCT04368858

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.
Description: In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
Study: NCT01681147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self monitoring of blood glucose levels
Description: Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
Study: NCT02971176

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose protocol computed tomography
Description: Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose protocol computed tomography
Description: Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
Study: NCT02845063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: concentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: concentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eccentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eccentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ACE genotyping
Description: Subjects will be genotyped for the ACE-I/D gene polymorphism.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ACE genotyping
Description: Subjects will be genotyped for the ACE-I/D gene polymorphism.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ACE genotyping
Description: Subjects will be genotyped for the ACE-I/D gene polymorphism.
Study: NCT02071901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag olamine
Description: Given PO
Study: NCT03801525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion
Study: NCT02845063

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ACE genotyping
Description: Subjects will be genotyped for the ACE-I/D gene polymorphism.
Study: NCT03703219

Intervention type: OTHER
Intervention: Mothers Touch Program
Description: Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
Study: NCT00555048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01256736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
Study: NCT03746665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal serogroup A conjugate vaccine
Description: Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
Study: NCT01124188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higher-dose venlafaxine
Description: Dosing of venlafaxine will range from 187.5-300 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-dose venlafaxine
Description: Dosing of venlafaxine will range from 187.5-300 mg/day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive management
Description: Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy for Depression and Pain
Description: PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
Study: NCT02120599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use supplementary food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn-soy blend

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: corn-soy blend

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UNIMMAP
Study: NCT01645098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg IV, additional doses of 0.5 mg/kg as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 mcg/kg/hr IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 mcg/kg/hr IV
Study: NCT00479648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated trivalent influenza vaccine
Study: NCT02048592

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impact-Nutridrink
Description: IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink-Impact
Description: In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
Study: NCT03818204

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Levator Prosthesis (MLP)
Description: Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Levator Prosthesis (MLP)
Description: Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
Study: NCT02561871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
Study: NCT03656094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Description: Pembrolizumab plus chemotherapy
Study: NCT00987623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens
Description: Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
Study: NCT02236949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Practice Change Booster Intervention
Description: See experimental arm for a description of the intervention
Study: NCT04593693

Intervention type: DEVICE
Group type: OTHER
Intervention: Invia Motion Endure NPWT system
Description: lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
Study: NCT00488579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two policies of iron prophylaxis
Description: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two policies of iron prophylaxis
Description: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
Study: NCT03656094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus chemotherapy
Description: Placebo plus chemotherapy
Study: NCT00646841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (GITS)
Description: 4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
Study: NCT03590522

Intervention type: GENETIC
Intervention: Ryanodine Receptor 2 gene expression
Description: Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.

Intervention type: GENETIC
Intervention: Ryanodine Receptor 2 gene expression
Description: Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
Study: NCT03491553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) OAV Therapy
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) OAV Therapy
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)
Study: NCT01180192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: either 8 L/minute O2 via face mask for 2 hours
Study: NCT00773708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
Study: NCT01400776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
Study: NCT03491553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) OAV Therapy
Description: Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)
Study: NCT03778723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue fentanyl
Description: Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
Study: NCT03778723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue fentanyl
Description: Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia